Radioimmunotherapy in non-Hodgkin lymphoma

Asher Chanan-Khan, Myron S. Czuczman

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Targeted therapy using monoclonal antibodies against a tumor-specific antigen is now an established mode of therapy in the management of malignant lymphomas. Radioimmunotherapy, a novel way of delivering systemic radiotherapy concurrently with immunotherapy, has finally appeared on the horizon, with promising results. Recent clinical trials have demonstrated the safety and efficacy of radioimmunoconjugates. Durable antitumor responses have been achieved, even in heavily pretreated patients. The optimal position that these novel agents should take in the algorithm of lymphoma therapy remains to be defined.

Original languageEnglish (US)
Pages (from-to)484-489
Number of pages6
JournalCurrent Opinion in Oncology
Issue number5
StatePublished - Sep 1 2002

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Radioimmunotherapy in non-Hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this